scholarly journals Bilateral Subfoveal Neurosensory Retinal Detachment Associated With MEK Inhibitor Use for Metastatic Cancer

2014 ◽  
Vol 132 (8) ◽  
pp. 1005 ◽  
Author(s):  
Tara A. McCannel ◽  
Bartosz Chmielowski ◽  
Richard S. Finn ◽  
Jonathan Goldman ◽  
Antoni Ribas ◽  
...  
Keyword(s):  
Retinal Detachment ◽  
Metastatic Cancer ◽  
Mek Inhibitor ◽  
Neurosensory Retinal Detachment

scholarly journals DETECTION OF NEUROSENSORY RETINAL DETACHMENT COMPLICATING DEGENERATIVE RETINOSCHISIS BY ULTRA-WIDEFIELD FUNDUS AUTOFLUORESCENCE IMAGING

Retina ◽  
2020 ◽  
Vol 40 (5) ◽  
pp. 819-824
Author(s):  
Anibal Francone ◽  
Nikisha Kothari ◽  
Matthew Farajzadeh ◽  
Hamid Hosseini ◽  
Pradeep Prasad ◽  
...  
Keyword(s):  
Retinal Detachment ◽  
Fundus Autofluorescence ◽  
Autofluorescence Imaging ◽  
Neurosensory Retinal Detachment

scholarly journals Dome-Shaped Macula and Foveal Neurosensory Retinal Detachment—A Case Series

2019 ◽  
Vol 09 (03) ◽  
pp. 151-160
Author(s):  
Torres Soriano Mitzy ◽  
Dimattia Jesica ◽  
Gordon Maximiliano
Keyword(s):  
Retinal Detachment ◽  
Case Series ◽  
Neurosensory Retinal Detachment

scholarly journals Optical coherence tomography in assessment chorioretinal blood flow in patients with central serous chorioretinopathy

2016 ◽  
Vol 15 (4) ◽  
pp. 39-47
Author(s):  
S. I. Zhukova ◽  
A. N. Zlobina ◽  
T. N. Iureva ◽  
A. A. Shchuko
Keyword(s):  
Blood Flow ◽  
Optical Coherence Tomography ◽  
Retinal Detachment ◽  
Central Serous Chorioretinopathy ◽  
Structural Changes ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Pathological Process ◽  
Optical Coherence ◽  
Neurosensory Retinal Detachment

Introduction and purpose. Central serous chorioretinopathy - a disease that manifests itself serous detachment of the neurosensory retina and / or retinal pigment epithelium (RPE). Chronic course of pathological process may be complicated by the development of subretinal neovascularization, and is accompanied by a decrease in visual functions. Despite the large number of studies, there are no pathogenetically oriented and effective methods of treatment of central serous chorioretinopathy today, because there is no consensus on the causes of its origin. To evaluate the accuracy of the information content of chorioretinal blood flow changes in patients with central serous chorioretinopathy, to compare the degree of changes of RPE and hemodynamic disorders in different forms of the disease. Materials and Methods. The study involved 26 patients with central serous chorioretinopathy aged 35 to 54 years. To assess chorioretinal blood flow the optical coherence tomography (OCT) in retinal angiography mode was included in the volume of diagnostic examination. Results. It was demonstrated that the choroidal vessels and RPE are an original target in the realization of the pathological process in central serous chorioretinopathy. The changes in the pigment epithelium and the neurosensory retinal detachment, whose height ranged from 53.4 to 513.0 m (238.3 ± 80.4 - in acute and - 215.5 ± 129.9 - in chronic diseases) were revealed in all patients. In 45 % of cases of acute and 67 % in patients with a chronic form of disease the neurosensory retinal detachment combined with RPE detachment, preventing recovery of macular interface on a background of medical actions. Prolonged existence of ischemia and RPE detachment is accompanied by severe progressive degenerative changes in the retina as a whole, causing resistance to treatment. Conclusions. OCT in angiography mode in the diagnosis of various forms of chorioretinal central serous chorioretinopathy allows visualizing blood flow, evaluating the extent and nature of the structural changes of the retina taking into account hemodynamic disorders. The revealed changes of RPE and choroid, as classification and prognostic criteria of the disease, determine the effectiveness of treatment measures and prognosis of disease.

Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 6023-6023 ◽  
Author(s):  
Vivek Subbiah ◽  
Robert J. Kreitman ◽  
Zev A. Wainberg ◽  
Jae Yong Cho ◽  
Jan H.M. Schellens ◽  
...  
Keyword(s):  
Metastatic Cancer ◽  
Treatment Options ◽  
Braf Inhibitor ◽  
Progression Free Survival ◽  
Credible Interval ◽  
Anaplastic Thyroid Cancer ◽  
Mek Inhibitor ◽  
Braf V600e ◽  
Open Label ◽  
Dismal Prognosis

6023 Background: ATC is a rare, aggressive malignancy with a dismal prognosis. Median overall survival (OS) is < 6 mo. Combined BRAF and MEK inhibition is efficacious in BRAF V600–mutated melanoma and lung cancer. One-fourth of ATCs harbor activating BRAF V600E mutations; thus, D (BRAF inhibitor) + T (MEK inhibitor) was evaluated as a treatment for pts with BRAF V600E–mutated ATC. Methods: In this phase 2, open-label trial (NCT02034110), pts with BRAF V600E mutations in 9 rare tumor types, including ATC, received continuous D (150 mg BID) + T (2 mg QD) until unacceptable toxicity, disease progression, or death. Eligible pts had advanced or metastatic cancer with no standard-of-care treatment options. The primary endpoint was investigator-assessed overall response rate (ORR). Secondary endpoints included duration of response (DOR), progression-free survival (PFS), OS, and safety. We report data from the ATC cohort. Results: 16 pts with BRAF V600E–mutated ATC had evaluable data with a median follow-up time of 47 wk (range 4-120 wk). BRAF V600E mutations were centrally confirmed in 15/16 pts. Median age was 72 y; all 16 pts had undergone prior tumor radiation and/or surgery and 6/16 pts (38%) had received ≥1 prior line of systemic therapy. Investigator-assessed confirmed ORR was 69% (11/16; 95% CI, 41%-89%), with 7/11 responses ongoing at the time of data cut. The Bayesian estimate of ORR was 69% (95% credible interval, 47%-87%) with a 100% probability that this ORR exceeded the 15% historical RR. Median DOR, PFS, and OS were not estimable due to insufficient progression and death events. Kaplan-Meier estimates of DOR, PFS, and OS at 12 mo were 90%, 79%, and 80%, respectively. The safety population comprised 100 pts enrolled in 7/9 histologies. Among all pts, 92% had an AE. Common AEs of any grade for all histologies were fatigue (38%), pyrexia (37%), and nausea (35%). In the ATC cohort, the most common grade 3/4 events were hyponatremia (19%), pneumonia (13%), and anemia (13%). Conclusions: D+T combination therapy significantly improved outcomes in ATC with a favorable safety profile. This regimen represents a clinically meaningful therapeutic advance for pts with advanced/metastatic BRAF V600–mutated ATC. Clinical trial information: NCT02034110.

scholarly journals Acute exudative polymorphous vitelliform maculopathy during pembrolizumab treatment for metastatic melanoma: a case report

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ine Lambert ◽  
Giuseppe Fasolino ◽  
Gil Awada ◽  
Robert Kuijpers ◽  
Marcel ten Tusscher ◽  
...  
Keyword(s):  
Retinal Detachment ◽  
Checkpoint Inhibitors ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Anterior Segment ◽  
Subretinal Fluid ◽  
Additional Treatment ◽  
Central Visual Field ◽  
Immunomodulating Therapy ◽  
Neurosensory Retinal Detachment

Abstract Background The use of immunomodulating therapy to treat various cancers has been on the rise and these immune checkpoint inhibitors are known to cause ocular side effects. In this article a case of acute exudative polymorphous vitelliform maculopathy (AEPVM) is reported which developed during a first line treatment with pembrolizumab. Case presentation A 54-year-old woman was referred because of blurry vision in both eyes with a yellow spot in the central visual field of the left eye. These symptoms started after four treatments with pembrolizumab (a monoclonal antibody against the programmed cell death receptor-1) for a metastatic recurrent vaginal mucosal melanoma. Her best corrected visual acuity was 10/10 in both eyes with a correction of + 2.00 bilaterally. There were no inflammatory findings in the anterior segment or the vitreous. Fundoscopy revealed an attenuation of the foveal reflex with subtle yellow-white subretinal macular deposits (vitelliform lesions) in both eyes. Fluorescein angiography did not show staining or leakage in the mid-phase, neither a late staining. Spectral-domain optical coherence tomography of the macula illustrated bilateral neurosensory retinal detachment with a thick, highly reflective band at the outer photoreceptor segment. En face structural OCT at the level of the photoreceptors showed focal areas of increased signal corresponding to hyperreflective vitelliform material. The treatment with pembrolizumab was ceased immediately. During the following visits we slowly saw an improvement of the neurosensory retinal detachment. After almost four months a total resolution of the subretinal fluid was visualized in both eyes without the use of additional treatment, though the vitelliform deposits persisted. Conclusions The development of AEPVM in melanoma patients could be triggered by treatment with Pembrolizumab. Pembrolizumab has the potential to disturb indirectly the retinal pigment epithelium homeostasis with accumulation of lipofuscin deposits and subretinal fluid, both signs of AEPVM.

Sign in / Sign up

Export Citation Format

Share Document